
- /
- Supported exchanges
- / US
- / MDIT.PINK
Medite Cancer Diagnostics Inc (MDIT PINK) stock market data APIs
Medite Cancer Diagnostics Inc Financial Data Overview
Medite Cancer Diagnostics, Inc. operates as a medical technology company. It develops, manufactures, and markets molecular biomarkers, medical devices, and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions and related diseases. The company offers USE 33, an ultrasonic decalcification instrument that automatically runs the process under controlled temperatures; TPC 15 Duo and Trio, a tissue processing instrument; TES 99 and TES Valida cooling units; and M530, A550, M380 microtomes for tissue sectioning. It also provides M630, a freezing microtome; TST44, a robotic multi-staining system; COT 20, a linear staining system; and RCM 9000, ACS 720, and TWISTER robotic coverslippers. In addition, the company develops SoftKit device for the self-collection of a sample that can be evaluated to provide an assessment of the health of the entire female genital tract. It sells its products through direct sales and distributors in the United States, China, Europe, and North Africa. The company serves histology and cytology laboratories associated with hospitals or research institutions, and independent laboratories. Medite Cancer Diagnostics, Inc. is based in Orlando, Florida.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Medite Cancer Diagnostics Inc data using free add-ons & libraries
Get Medite Cancer Diagnostics Inc Fundamental Data
Medite Cancer Diagnostics Inc Fundamental data includes:
- Net Revenue: 8 133 K
- EBITDA: -3 732 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-02-28
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Medite Cancer Diagnostics Inc News

MEDITE Cancer Diagnostics Appoints Joel Kanter To Its Board As An Independent Director
ORLANDO, Fla., Nov. 15, 2017 (GLOBE NEWSWIRE) -- MEDITE Cancer Diagnostics, Inc. (OTCQB:MDIT) (the “Company”), specializing in the development, manufacturing and marketing of molecular biomarker...


MEDITE Cancer Diagnostics Reports 2017 Third Quarter Financial Results
ORLANDO, Fla., Nov. 14, 2017 (GLOBE NEWSWIRE) -- MEDITE Cancer Diagnostics, Inc. (OTCQB:MDIT) (the “Company”), specializing in the development, manufacturing and marketing of molecular biomarker...

MEDITE Cancer Diagnostics Reports Appointments of New Chairman of the Board and Chief Executive Officer
ORLANDO, Fla., Nov. 08, 2017 (GLOBE NEWSWIRE) -- MEDITE Cancer Diagnostics, Inc. (OTCQB:MDIT) (the “Company”), specializing in the development, manufacturing and marketing of molecular biomarker...

MEDITE Cancer Diagnostics Reports Closing of $5.4 Million Private Financing, Providing Working Capital to Drive Commercial Plan Execution
ORLANDO, Fla., Oct. 03, 2017 (GLOBE NEWSWIRE) -- MEDITE Cancer Diagnostics, Inc. (OTCQB:MDIT) (the “Company”), specializing in the development, manufacturing and marketing of molecular biomarker...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.